1. Introduction {#sec1}
===============

Lung cancer ranks the first in the morbidity and mortality of human malignancies and keeps the leading position of all common malignant tumors worldwide. Histopathologically, lung cancers are classified into small cell lung cancer and nonsmall cell lung cancer. The latter is further classified into squamous cell carcinoma, adenocarcinoma, and large cell caicinoma, according to its morphologic patterns. Among which, squamous cell carcinoma is the most common, which accounts for 40%--70% \[[@B1]\]. Squamous cell carcinoma originates from the bronchial epithelial cell. Currently, the mechanism of the initiation, development, and dissemination of human lung squamous carcinomas (HLSCs) is still unclear.

Proteomics provides a new opportunity to reveal the carcinogenic mechanism of HLSC. The comparative proteomics compares the tumor and its origin tissue may reflect the carcinogenesis. However, the main obstacle for proteomics analysis is the heterogeneity of the soft tumor tissues. In order to improve the accuracy of the results, it is necessary to purify the target cells from the heterogeneous tissues. Laser capture microdissection (LCM) is one of the best technologies for cell purification \[[@B2]--[@B6]\]. The quantitative proteomics is one of the emerging fields for tumor proteomics study; isotope labeling relative and absolute quantification (iTRAQ) is a new technique in quantitative proteomics, which could be used to identify and quantify the protein expression levels and identify the small changes of protein expression in different tissues.

In this study, LCM was used to purify the target cells from HLSC tissues and matched NBE; iTRAQ followed by 2D-LC/Q-STAR mass spectrometry was performed to separate and identify the differential expression proteins in LCM-purified HLSC tissues and matched NHBE.

2. Materials and Methods {#sec2}
========================

2.1. Sample Collection, Laser Capture Microdissection, and Protein Extraction {#sec2.1}
-----------------------------------------------------------------------------

Twenty pairs of HSCL tissues and matched normal bronchial epithelium tissues from the LSCC patients undergoing curative surgery and receiving neither chemotherapy nor radiotherapy were obtained from Department of Cardiothoracic Surgery, The Second Xiangya Hospitals of Central South University, China. The patients signed an informed consent form for the study which was approved by the local ethical committee. Samples were diagnosed by histopathology. 10 pairs of the tissues were used for iTRAQ, and the other 10 pairs of the tissues for Western blotting, respectively. Tissues were frozen in −70°C.

LCM was performed with a Leica AS LMD system to purify the interest cells from HSCL tissues and matched NBE tissues as previously described by us. Breifly, frozen sections (8 mm) from each HLSC and NBE tissues were prepared using a Leica CM 1900 cryostat (Leica) at −25°C. The sections were placed on a membrane-coated glass slides (Leica), fixed in 75% alcohol for 30 s, and stained with 0.5% violet-free methyl green (Sigma). The stained sections were air-dried and then subjected to LCM.

The microdissected cells were dissolved in lysis buffer (7 M urea, 2 M thiourea, 65 mM DTT, 0.1 mM PMSF) at 4°C for 1 h and then centrifuged at 12 000 rpm for 30 min at 4°C. The supernatant was collected, and the protein concentration was determined by 2D Quantification kit (Amersham Biosciences). To diminish the effect of sample biological variation on the results of a proteomics analysis, equal amounts of proteins from the microdissected cells of 10 different individuals were pooled to generate one common sample iTRAQ labeling.

2.2. Protein Digestion and Labeling with iTRAQ Reagents {#sec2.2}
-------------------------------------------------------

Trypsin digestion and iTRAQ labeling were performed according to the manufacturer\'s protocol (Applied Biosystems). Briefly, 100 *μ*g protein of each pooled sample was reduced and alkylated and then digested overnight at 37°C with trypsin (mass spectrometry grade; Promega) and labeled with iTRAQ reagents (Applied Biosystems) as follows: NBE, iTRAQ reagent 113; and HLSC, iTRAQ reagent 115. The labeled digests were then mixed and dried.

2.3. Off-Line 2D LC-MS/MS {#sec2.3}
-------------------------

The mixed peptides were fractionated by strong cation exchange (SCX) chromatography on a 20AD HPLC system (Shimadzu) using a polysulfoethyl column (2.1 × 100 mm, 5 *μ*m, 300 Å; The Nest Group Inc.) as previously described by us \[[@B26]\]. Briefly, the mixed peptides were desalted with Sep-Pak Cartridge (Waters), diluted with the loading buffer (10 mM KH2PO4 in 25% ACN, pH 2.8), and loaded onto the column. Buffer A was identical in composition to the loading buffer, and buffer B was same as buffer A except of containing 350 mM KCl. Separation was performed using a linear binary gradient of 0--80% buffer B in buffer A at a flow rate of 200 *μ*l/min for 60 min. The absorbance at 214 nm and 280 nm was monitored, and a total of 30 SCX fractions were collected along the gradient.

Each SCX fraction was dried down, dissolved in buffer C (5% ACN, 0.1% FA), and analyzed on Qstar XL (Applied Biosystems) as previously described by us \[[@B26]\]. Briefly, peptides were separated on a reverse-phase (RB) column (ZORBAX 300SB-C18 column, 5 *μ*m, 300 Å, 0.1 × 15 mm; Micromass) using a 20AD HPLC system (Shimadzu). The HPLC gradient was 5--35% buffer D (95% ACN, 0.1% FA) in buffer C at a flow rate of 0.2 *μ*l/min for 65 min. Survey scans were acquired from 400 to 1800 with up to 4 precursors selected for MS/MS from m/z 100--2000 using a dynamic exclusion of 30S. The iTRAQ-labeled peptides fragmented under CID conditions to give reporter ions at 113.1 and 1151 Th. The ratios of peak areas of the iTRAQ reporter ions reflect the relative abundances of the peptides and, consequently, the proteins in the samples. Larger, sequence-information-rich fragment ions were also produced under these MS/MS conditions and gave the identity of the protein from which the peptide originated.

2.4. Data Analysis {#sec2.4}
------------------

The ProteinPilot 3.0 software program (ABI, USA) was used to perform Protein identification and quantification analysis for the iTRAQ experiment. Identified proteins were grouped by the software to minimize redundancy; all peptides used for the calculation of protein ratios were unique to the given protein or proteins within the group. The protein confidence threshold cutoff for this study is ProtScore 1.3 (unused) with at least one peptide with 95% confidence. The relative protein abundances were analyzed by the signature ion ratio (m/z, 115/113): the ratio ≥1.2 and ≤0.8 as the differential expression proteins.

2.5. Western Blotting {#sec2.5}
---------------------

Western blotting was performed in ten pairs of microdissected HLSC and NBE. Briefly, 30--50 *μ*g of purified protein was separated by 10% SDS-PAGE and transferred to PVDF membrane (Bio-Rad). The blots were incubated for 2 h at room temperature in TBST (20 mM Tris-Cl, 140 mM NaCl, pH 7.5, 0.05% Tween-20) containing 5% skim milk and then were incubated with monoclonal mouse anti-HSPB1 (dilution 1 : 1000, Abcam), monoclonal rabbit anti-CKB (dilution 1 : 200, Santa Cruze), polyclonal rabbit anti-human S100A8/A9, and polyclonal mouse anti-human SCCA1 (dilution 1 : 200, Santa Cruze) overnight at 4°C. After washing three times in TBST, membranes were incubated with a horse radish peroxidase conjugated secondary antibody (dilution 1 : 3,000, Amersham Biosciences) for 1 h at room temperature. The blots were developed using ECL detection reagent and quantitated by densitometry using ImageQuant image analysis system (Storm Optical Scanner). The *β*-actin was detected simultaneously as a loading control.

2.6. Tissue Microarray and Immunohistochemistry {#sec2.6}
-----------------------------------------------

The tissue microarray containing 30 lung squamous cell carcinoma, 30 metastatic carcinoma, 20 normal lung tissues, and 20 other types of lung cancer (lung adenocarcinoma, large cell carcinoma, small cell carcinoma) was from AURAGENE. The detailed information of the tissues is provided in [Table 1](#tab1){ref-type="table"}.

Serial sections (4 *μ*m) were cut from the tissue microarray, deparaffinized, rehydrated, and treated with an antigen retrieval solution (10 mmol/L sodium citrate buffer, pH 6.0). Endogenous peroxidase was blocked using 3% hydrogen peroxide in methanol for 20 min. Nonspecific sites were blocked for 20 min using 1% normal serum in PBS. Sections were incubated for 2 h with a dilution of 1 : 200 polyclonal rabbit anti-human S100A8/A9 or SCCA1 and then were incubated with 1 : 1000 dilution of biotinylated secondary antibody followed by avidin-biotin peroxidase complex (DAKO) according to the manufacturer\'s instructions. Finally, tissue sections were incubated with 3′, 3′-diaminobenzidine (Sigma) until a brown color developed and counterstained with Harris\' modified hematoxylin. In negative controls, primary antibodies were omitted.

2.7. Evaluation of Staining {#sec2.7}
---------------------------

Immunostaining was blindly evaluated by two observers in an effort to provide a consensus on staining patterns. Each case was rated according to a score that added a scale of intensity of staining to the area of staining. At least 10 high-power fields were chosen randomly, and \>1000 cells were counted for each section. The positive intensity of staining was graded on the following scale: 0, no staining; 1+, pale yellow stained; 2+, tan-yellow stained; and 3+, brown stained. The negative intensity of staining was evaluated as follows: 0, \<5% of tissue stained negative; 1+, 5%--25% of tissue stained negative; 2+, between 25% and 50% stained negative; 3+, 50%--75% stained negative; and 4+, \>75% stained negative. The minimum score when summed (positive stained + negative stained) was therefore 2 and the maximum, 7. A combined staining score (positive stained + negative stained) of \<2 was considered to be negative staining (−); a score between 2 and 3 was considered to be weak staining (+); between 3 and 6 was considered to be moderate staining (++); and between 6 and 7 was considered to be strong staining (+++).

2.8. Statistical Analysis {#sec2.8}
-------------------------

One-way analysis of variance (ANOVA) and LSD analysis (SPSS 12.0) were used in this study. All statistical tests were two-sided. Differences were considered statistically significant for *P* values \< 0.05.

3. Results {#sec3}
==========

3.1. Identification of Differentially Expressed Proteins in HLSC and NBE Using iTRAQ Labeling and 2D LC-MS/MS {#sec3.1}
-------------------------------------------------------------------------------------------------------------

A total of 96 differentially expressed proteins were identified by iTRAQ labeling and 2D LC-MS/MS, among which 49 upregulated and 47 downregulated proteins in HLSC ([Table 2](#tab2){ref-type="table"}). MS/MS spectrum used for the identification and quantitation of CKB is shown in [Figure 1](#fig1){ref-type="fig"}.

Biological functions and subcellular location of the identified 96 proteins were searched in EMBL-EBI and EXPASY database. The most common differential expression proteins were located in the cytoplasm, followed by nuclear proteins, secreted proteins, and mitochondrial proteins. The locations of the proteins were concomitant with their functions, which were structural proteins, metabolic enzymes, signal transduction proteins, cell adhesion, and proliferation-related proteins ([Figure 2](#fig2){ref-type="fig"}).

3.2. Validation of Differentially Expressed Proteins Indentified by Proteomics {#sec3.2}
------------------------------------------------------------------------------

Five proteins (HSPB1, S100A8/A9, CKB, and SCCA1) identified by MS analysis were chosen for verification. Western blotting was performed to detect the expressional levels of the four proteins in 10 cases of LCM-purified NBE and HLSC. As shown in [Figure 3](#fig3){ref-type="fig"}, HSPB1 and S100A8/A9 were upregulated, whereas CKB and SCCA1 were downregulated in the HLSC versus NBE (*P* \< 0.05), which is consistent with the findings in MS analysis.

3.3. Detection of the Expression of the Differential Proteins by TMA and Immunohistochemistry {#sec3.3}
---------------------------------------------------------------------------------------------

The expressions of SCCA1, S100A8/A9 in 30 squamous cell carcinoma, 30 metastatic carcinoma, and 20 nonsquamous cell carcinoma (8 adenocarcinoma, 6 large cell carcinoma, 6 small cell carcinoma) were detected by TMA and immunohistochemisry. As shown in [Figure 4](#fig4){ref-type="fig"} and [Table 3](#tab3){ref-type="table"}, the expressions of SCCA1 in lung squamous cell carcinoma, other types of lung carcinoma, and metastatic carcinoma were lower than those in normal lung tissue (*P* \< 0.05). As shown in [Figure 5](#fig5){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}, S100A8/A9 was expressed in all types of lung cancer and normal tissues. Yet, the expression of S100A8 in lung squamous cell carcinoma was stronger than that in normal tissues and other types of lung cancer tissues (*P* \< 0.05). As shown in [Figure 6](#fig6){ref-type="fig"} and [Table 5](#tab5){ref-type="table"}, the expression of S100A9 in cancer tissues including lung squamous cell carcinoma, metastatic carcinoma, and other types of lung cancer was stronger than in normal tissues (*P* \< 0.05).

4. Discussion {#sec4}
=============

Recently, numerous successful explorations about carcinogenic molecular mechanisms of HLSC on gene and transcription were reported. Compared with genome and transcriptome, which is relatively static and will be transcribed into a variety of functionally distinct proteins, proteome may provide a more realistic picture of function aberrations in cancer cells. Proteomics has become the frontier era of the postgenomic; the new methods and achievements are emerging in large number. Traditional 2-DE technique has been used widely for comparative proteomics with a significant achievement, but also there is disadvantagedness. iTRAQ quantitative proteomics can overcome that deficiencies (such as identified membrane proteins) and increase the number and types of differential expression proteins. In contrast to 2-DE, iTRAQ technology has a better repeatability and quantification.

In the study, LCM was used to purify the target cells from HLSC tissues and matched NHBE, respectively. A stable isotope-labeled strategy using iTRAQ, followed by 2D-LC/Q-STAR mass spectrometry, was performed to separate and identify the differential expression proteins. A total of 96 differential expression proteins in the LCM-purified HLSC and NHBE were identified.

Among the differential expression proteins, HSPB1(HSP27) is heat shock protein family member, which has important biological functions, a chaperone protein involved in regulation of cell proliferation, differentiation, apoptosis and signal transduction, and so forth. Induced epithelial-mesenchymal transition (EMT) in human lung cancer cells (adenocarcinoma cells), HSPB1, was high-regulated and involved in the regulation of cell migration, adhesion and invasion \[[@B7]\]. In the colon, prostate, and breast cancer, HSPB1 expression was associated with tumor occurrence and metastasis. HSPB1 was high-regulated, suggesting the poor prognosis and resistance to drugs \[[@B8]--[@B11]\]. Guo et al. found that the functional HSPB1 promoter −1271G \> C variant may affect lung cancer susceptibility and survival by modulating endogenous HSPB1 synthesis levels \[[@B12]\]. The research showed HSPB1 protein and its phosphorylation increased in parallel with enhanced metastatic potentials of hepatocellular carcinoma (HCC) cells; HSPB1 knockdown significantly suppressed cells migration and invasion and induced cell apoptosis \[[@B13]\]. Ye et al. showed that upregulated HSPB1 expression was potentially involved in human oral squamous cell carcinoma growth and metastasis \[[@B14]\]. In our study, HSPB1 was upregulated in HLSC compared with NHBE, confirmed by Western blot analysis. It was suggested that HSPB1 might play a certain role in carcinogenic of HLSC.

CKB (creatinekinase B) is a member of the creatine kinase family, that exists widely in as skeletal muscle, myocardial, nerve tissue, and mitochondria. CKB participated in energy signaling pathways and catalyzed phosphate group reversibly from creatine phosphate to ADP to generate ATP and creatine. CKB expressed in the organization demanded high energy, as a nuclear "energy supplier". CKB was downregulated protein in human prostate cancer cells associated with progression \[[@B15]\]. Reduced expression has been reported in colon, and renal cancer compared with matched adjacent normal tissues \[[@B16], [@B17]\]. Our finding of reduced levels of CKB in human lung squamous carcinoma suggests a novel association for CKB with HLSC which needs to be investigated further.

SCCA1 (Squamous cell carcinoma antigen 1) also named SERPINB3 (serine protease inhibitor3) belonged to serine protease inhibitor family, that was physiologically found in normal squamous epithelium but overexpressed in squamous cell carcinoma (lung, cervical, esophagus, etc.). The biological role of this serpin in carcinogenesis has not been defined. On the one hand, SCCA1 can decrease NK tumour invasion \[[@B18]\] and inhibit apoptosis by inhibiting P38 phosphorylation and release of C cytochromes \[[@B19], [@B20]\]. Elevated levels of SCCA1 have been reported in liver, esophagus, mammary carcinoma, and so forth, associated with malignant cancer, prognosis, and recurrence \[[@B21]\]. In a previous study, it was reported that SCCA1 expression levels were associated with tumor progression. Increasing number of reports suggests that SCCA has been implicated as a tumor marker for squamous \[[@B22]\]. Interestingly, our finding is that SCCA1 levels were downregulated in human lung squamous carcinoma compared with corresponding normal tissue. Our laboratory reported that SCCA1 levels were downregulated in nasopharyngeal carcinoma by promoter methylation \[[@B23]\]. Whether lung squamous carcinoma exists in promoter methylation, further analysis of the expression of SCCA1 in preneoplastic lesions for squamous cell carcinoma of the lung is needed.

Heterodimer S100A8/A9 is the member of calcium- binding protein S100 protein family, the inflammation factor, and inhibition of casein kinase I, II activity. Physically, S100A8/A9 is expressed as the early stages of cell differentiation in bone marrow and granulocytes and monocytes in circulation. Some inflammatory diseases, such as rheumatoid rheumatoid arthritis, inflammatory bowel disease, chronic pneumonia, their epithelial cells, and the cells of inflammatory exudate in early stage of inflammatory diseases express S100A8/A9. Elevated levels of S100A8/A9 have been reported in lung, stomach, breast, pancreatic, prostate cancer, and so forth. In addition, S100A9 has correlation with the poor differentiation of breast, lung, and thyroid cancer \[[@B26], [@B24]--[@B27]\]. Iikawa reveals a novel role for myeloid-derived S100A8/A9 in activating MAPK and NF-*κ*B signaling pathways associated with colon tumorigenesis and in promoting tumor growth and metastasis \[[@B28]\]. Our findings are consistent with the reported that S100A8/A9 is upregulated in human lung squamous carcinoma compared with corresponding normal tissue. Although many possible functions have been proposed for S100A8/A9, its biological role still remains to be defined.

5. Conclusions {#sec5}
==============

In conclusion, our data suggest that the several differential expression proteins may play a key role in human lung squamous carcinoma. Known to that during the development of human lung squamous cell carcinoma, bronchial epithelial cells exhibit a progressive series of morphologically distinct changes: hyperplasia, squamous metaplasia, dysplasia, carcinoma in situ, and finally invasive squamous cell carcinoma. We seek to identify differential expression proteins that can be used to monitor these premalignant changes under the assumption that these morphologic changes are accompanied by abnormal expression proteins. Thus, additional research using a larger number of tumor specimens is needed to confirm our findings more assuredly and we will make greater efforts to elucidate the precise molecular mechanisms of how the protein acts on the carcinogenesis in future works.

Author\'s Contribution {#sec6}
======================

X. Yan, C. Lan-Qin, and J. Long-Yu contributed equally to this work.

This work is supported by the National Natural Science Foundation of China (no. 30972970), Program for New Century Excellent Talents in University (2007-0861), Nature Scientific Foundation of Hunan Province (08JJ6010), and Scientific Research Foundation of Department of Public Health of Hunan Province (B2007-068; B2010-037); Scientific Research Fund of Department of Education of Hunan Province (09C837), China.

![The fragment ion spectra of peptide sequence tag (PST) from CKB protein, highlighting the relative abundances of overexpression in NHBE. The ion assignments are as follows: 113: NHBE; and 115: HLSC.](JBB2012-510418.001){#fig1}

![Biological functions and subcellular location of the identified 96 proteins. (a) A pie chart representing the distribution of the identified 96 proteins according to their cellular locations; (b) A pie chart representing the distribution of the identified 96 proteins according to their biological function.](JBB2012-510418.002){#fig2}

![Representative results of Western blotting analysis of HSPB1, CKB, S100A8/A9, and SCCA1 in HLSC (CA) and NHBE (N). *β*-actin was used as a loading control.](JBB2012-510418.003){#fig3}

![Immunohistochemistry staining in tissue chip of SCCA1 protein expression in lung cancer tissue and normal tissues ((a) normal lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell carcinoma tissues).](JBB2012-510418.004){#fig4}

![Immunohistochemistry staining in tissue chip of S100A8 protein expression in lung cancer tissue and normal tissues ((a) normal lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell carcinoma tissues).](JBB2012-510418.005){#fig5}

![Immunohistochemistry staining in tissue chip of S100A9 protein expression in lung cancer tissue and normal tissues ((a) normal lung tissue, (b) lung squamous cell carcinomas, (c) metastatic carcinoma, (d) adenocarcinoma, (e) small cell carcinoma, (f) large cell carcinoma tissues).](JBB2012-510418.006){#fig6}

###### 

The clinicopathological parameters of the 100 tissue specimens.

  Classification               Number
  ---------------------------- --------
  Gender                       
   Male                        84
   Female                      16
  Age                          
   ≥55                         68
   \<55                        32
  Histological type            
   Squamous cell carcinoma     30
   High differentiated         5
   Moderately differentiated   14
   Poorly differentiated       11
   Adenocarcinoma              8
   Large cell carcinoma        6
   Small cell carcinoma        6
   Lymph node metastasis       30
  Positive                     
   Normal lung tissue          20

###### 

Differential expressed proteins in LCM-purified HLSC and NHBE identified by mass spectrometry.

  No. of proteins   Coverage (%)   UniprotKB        AC            Name        Peptides   115 : 113
  ----------------- -------------- ---------------- ------------- ----------- ---------- -----------
   1                62.34          IPI00554648.3    P05787        KRT8        60         0.4098
   2                60.05          IPI00479145.2    P08727        KRT19       51         0.6193
   3                56.53          IPI00745872.2    P02768        ALB         40         0.5735
   4                59.8           IPI00009867.3    P13647        KRT5        68         0.7839
   5                54.17          IPI00019502.3    P35579        MYH9        32         1.6587
   6                39.41          IPI00007752.1    P68371        TUBB2C      37         0.1989
   7                35.87          IPI00784154.1    P10809        HSPD1       30         1.5497
   8                34.28          IPI00479186.5    P14618        PKM2        21         1.5827
   9                34.2           IPI00844215.1    Q13813        SPTAN1      17         0.5947
   10               42.7           IPI00450768.7    Q04695        KRT17       25         0.7824
   11               30.05          IPI00219018.7    P04406        GAPDH       22         1.5761
   12               28.96          IPI00845339.1    P08107        HSPA1A/1B   15         0.5216
   13               27.82          IPI00022204.2    P29508        SERPINB3    16         0.3215
   14               31.05          IPI00554788.5    P05783        KRT18       32         0.5866
   15               50.34          IPI00300725.7    P02538        KRT6A       59         1.6359
   16               24.25          IPI00553177.1    P01009        SERPINA1    13         0.651
   17               23.08          IPI00654755.3    P68871        HBB         19         1.4246
   18               22.65          IPI00455383.4    Q00610        CLTC        12         0.6788
   19               23.9           IPI00003362.2    P11021        HSPA5       13         1.9385
   20               20.99          IPI00025252.1    P30101        PDIA3       14         1.477
   21               19.32          IPI00218914.5    P00352        ALDH1A1     11         0.3403
   22               35.01          IPI00217963.3    P08779        KRT16       19         1.7771
   23               18.49          IPI00872684.1    P15311        EZR         9          0.3327
   24               16.7           IPI00013808.1    O43707        4ACTN4      14         0.4979
   25               33.95          IPI00290077.1    P19012        KRT15       20         0.6399
   26               16             IPI00219757.13   P09211        GSTP1       13         0.5584
   27               15.06          IPI00000105.4    Q14764        MVP         7          0.516
   28               14.96          IPI00645078.1    P22314        UBA1        8          1.345
   29               14.66          IPI00788802.1    P29401        TKT         8          1.4856
   30               13.96          IPI00020599.1    P27797        CALR        7          2.1548
   31               13.57          IPI00169383.3    P00558        PGK1        8          0.6459
   32               13.23          IPI00887678.1                  LOC654188   8          2.2579
   33               12.44          IPI00640741.1    Q06830        PRDX1       6          6.5599
   34               12.12          IPI00604620.3    P19338        NCL         7          1.5576
   35               12.1           IPI00893881.1    Q53G64        AGR2        14         0.4388
   36               11.27          IPI00853068.1    Q86YQ1        HBA         11         1.372
   37               11.23          IPI00816252.1                  H2BFS       18         1.4498
   38               11.14          IPI00657682.2    P08263        GSTA1       6          0.2536
   39               11.01          IPI00643384.2    A6NLG9        BGN         5          0.2803
   40               23.25          IPI00550661.2    P13646        KRT13       20         2.3013
   41               38.63          IPI00384444.5    P02533        KRT14       19         1.448
   42               10.4           IPI00027497.5    P06744        GPI         4          2.4216
   43               9.95           IPI00027462.1    P06702        S100A9      7          3.1824
   44               9.85           IPI00215948.4    P35221        CTNNA1      5          0.6596
   45               9.76           IPI00453473.6    P62805        HIST1H4I    5          15.7322
   46               9.42           IPI00794543.1    A8K1M2-cDNA   FLJ75174    4          0.3772
   47               9.08           IPI00549248.4    P06748        NPM1        9          2.033
   48               8.97           IPI00221226.7    P08133        ANXA6       4          0.6198
   49               8.63           IPI00032140.4    P50454        SERPINH1    4          2.9965
   50               8.55           IPI00025512.2    P04792        HSPB1       20         3.9981
   51               8.14           IPI00798430.1    Q53H26        TF          4          0.6764
   52               35.45          IPI00011654.2    P07437        TUBB        28         1.5243
   53               8              IPI00022977.1    P12277        CKB         4          0.41
   54               7.84           IPI00307162.2    P18206        VCL         5          2.4223
   55               7.22           IPI00295400.1    P23381        WARS        3          1.4314
   56               6.92           IPI00792011.1    Q8NF12        CAPS        5          0.3241
   57               6.36           IPI00013415.1    P62081        RPS7        3          3.2407
   58               6.27           IPI00025465.1    P20774        OGN         4          0.1986
   59               6.24           IPI00853455.1    C9JIH9        CTSD        4          0.639
   60               6.19           IPI00152295.1    Q8TC71        SPATA18     3          0.4421
   61               9.34           IPI00829767.1    P01859        IGHG2       4          0.6251
   62               6              IPI00789551.1    A8MXP9        MATR3       5          2.0326
   63               6              IPI00871851.1    Q15019        SEPT2       4          1.3502
   64               6              IPI00291006.1    P40926        MDH2        3          1.924
   65               6              IPI00795633.1    Q8IWL5        CLU         3          0.3392
   66               5.95           IPI00423462.5    Q6N092        IGHA1       3          0.7002
   67               8.33           IPI00007047.1    P05109        S100A8      5          2.1281
   68               5.73           IPI00654709.1    Q6PKA6        ALDH3A1     3          0.431
   69               4.72           IPI00294834.6    Q12797        ASPH        2          2.3432
   70               6.6            IPI00027350.3    P32119        PRDX2       3          1.7333
   71               4.45           IPI00025086.3    P20674        COX5A       2          1.4661
   72               4.4            IPI00009032.1    P05455        SSB         2          0.6693
   73               4.4            IPI00060715.1    Q96CX2        KCTD12      2          0.7126
   74               4.31           IPI00646059.1    Q5VXV2        SET         2          2.3791
   75               4.13           IPI00216308.5    P21796        VDAC1       2          0.4488
   76               4.08           IPI00032179.2    P01008        SERPINC1    2          0.6734
   77               4.01           IPI00025796.3    O75489        NDUFS3      2          0.6022
   78               4              IPI00020042.2    P43686        PSMC4       2          0.603
   79               4              IPI00011126.6    P62191        PSMC1       2          0.6418
   80               3.71           IPI00883950.1    Q8TB01        CKAP4       2          2.3486
   81               2.95           IPI00420014.2    O75643        ASCC3L1     1          1.6656
   82               2.73           IPI00003944.1    P11182        DBT         1          0.5156
   83               2.58           IPI00479786.4    Q92945        KHSRP       1          1.9958
   84               2.38           IPI00419237.3    P28838        LAP3        1          1.7329
   85               2.34           IPI00024933.3    P30050        RPL12       1          1.7853
   86               2.19           IPI00219221.3    P47929        LGALS7      1          0.7374
   87               2.02           IPI00444204.1    Q6ZS74        ALB         1          2.0254
   88               2.02           IPI00847322.1    Q4ZJI1        SOD2        1          0.6501
   89               2.01           IPI00745729.2    A6PVW9        SELENBP1    1          0.5016
   90               2.01           IPI00375746.4    Q6ZN66        GBP6        1          4.68
   91               2              IPI00413654.3    Q13243        SFRS5       1          4.0553
   92               2              IPI00010133.3    P31146        CORO1A      1          1.5283
   93               2              IPI00221222.7    P53999        SUB1        1          7.5809
   94               2              IPI00024976.5    Q9NS69        TOMM22      1          2.5511
   95               2              IPI00888660.1                  SDHA        1          2.0706
   96               2              IPI00013895.1    P31949        S100A11     2          0.6028

Differentially labeled proteins are identified by QSTAR. The % coverage of analyzed peptides and Swiss-Prot accession number were shown for each protein. Proteins displaying an average fold-difference of ≥1.2-fold up- (+) or ≤0.8-fold down- (-) regulation between pairs of conditions where *P* \< 0.05 are shown (115: the group of HLSC; 113: the group of NHBE).

###### 

SCCA1 expression in various tissues by IHC.

  Classification              Number   ---   \+   ++--+++   *P*value
  --------------------------- -------- ----- ---- --------- ----------
  Squamous cell carcinomas    30       21    5    4         0.038^a^
  High differentiated         3        3     0    0         0.406^b^
  Moderately differentiated   11       9     2    0         
  Poorly differentiated       10       6     2    2         
  Normal lung tissue          20       9     10   1         
  Metastatic carcinoma        29       16    5    8         0.029^c^
  Other types                 20       12    6    2         0.001^d^

^a^ *P* \< 0.05 by LSD, squamous cell carcinomas versus normal lung tissue. ^b^*P* \> 0.05 by ANOVA, high differentiated versus moderately versus poorly. ^c^*P* \< 0.05 by LSD, metastatic carcinoma versus normal lung tissue. ^d^*P* \< 0.05 by LSD, other types versus normal lung tissue.

###### 

S100A8 expression in various tissues by IHC.

  Classification              Number   ---   \+   ++--+++   *P*value
  --------------------------- -------- ----- ---- --------- ----------
  Squamous cell carcinomas    30       1     5    24        0.000^a^
  High differentiated         3        0     0    3         0.705^b^
  Moderately differentiated   11       2     7    2         
  Poorly differentiated       10       6     2    2         
  Normal lung tissue          20       1     11   8         
  Metastatic carcinoma        29       0     11   18        0.007^c^
  Other types                 20       3     12   5         0.000^d^

^a^ *P* \< 0.05 by LSD, squamous cell carcinomas versus normal lung tissue. ^b^*P* \> 0.05 by ANOVA, high differentiated versus moderately versus poorly. ^c^*P* \< 0.05 by LSD, metastatic carcinoma versus normal lung tissue. ^d^*P* \< 0.05 by LSD, other types versus normal lung tissue.

###### 

S100A9 expression in various tissues by IHC.

  Classification              Number   ---   \+   ++--+++   *P* value
  --------------------------- -------- ----- ---- --------- -----------
  Squamous cell carcinomas    30       0     2    28        0.01^a^
  High differentiated         3        0     3    0         0.705^b^
  Moderately differentiated   11       9     2    0         
  Poorly differentiated       10       8     2    0         
  Normal lung tissue          20       0     10   10        
  Metastatic carcinoma        29       0     4    25        0.000^c^
  Other types                 20       0     2    18        0.000^d^

^a^ *P* \< 0.05 by LSD, squamous cell carcinomas versus normal lung tissue. ^b^*P* \> 0.05 by ANOVA, high differentiated versus moderately versus poorly. ^c^*P* \< 0.05 by LSD, metastatic carcinoma versus normal lung tissue. ^d^*P* \< 0.05 by LSD, other types versus normal lung tissue.

[^1]: Academic Editor: Kapil Mehta
